AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 41 min read$QTTB

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

Original reporting
tradingview.com
Published Nov 4, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$QTTBBearishLow
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but the company's pipeline progress and upcoming regulatory talks could mitigate longer‑term risk.

02

Market read

Primary relevance is to Q32 Bio shareholders; broader market impact is limited.

03

What to watch

Upcoming regulatory discussions and potential partnership options for the complement platform may provide upside not reflected in the loss figures.

Relevance 7/10Novelty 6/10Timing: post‑market today

Background

Q32 Bio is a clinical‑stage biotech focused on hair growth therapies. The 10‑Q filing includes trial updates and plans for regulatory engagement.

Company-level read

Ticker impact

$QTTBBearishMedium confidence
Context

Q32 Bio reported its Q3 2026 net loss of $8.9M and EPS of $(0.26), a fresh earnings disclosure from its 10‑Q filing.

Expected impact

likely pressure as investors price in the larger YoY loss despite per‑share improvement

Evidence & confidence

Earnings miss on loss magnitude outweighs the per‑share narrowing; micro‑cap volatility suggests a modest downside bias.

Market effects

Sector

Biotech sector may see slight caution as Q32 Bio's loss highlights ongoing development risk.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact given the company's small size.

Counterpoint

What could challenge this read

The narrowing loss per share could signal improving cost structure, offering a buying opportunity if the market overreacts to the headline loss.

Key entities

  • company
    Q32 Bio Inc.

    Biotech firm reporting Q3 2026 results.

  • company
    Akebia

    Assumed future development of ADX‑097 after asset sale.

Read at source← All news

StoryQ32 Bio reports Q3 2026 results and advances bempikibart toward Phase 3

Also covered by

4 outlets

Related articles

NOV 4
$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

rttnews.com2 min
NOV 4
$QTTBHigh

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update -- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026

SEC EDGAR 8-K2 min
NOV 4
$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.

prnewswire.com3 min
SEP 30
$QTTBHighAI 8/10

Why is Q32 Bio stock surging today?

Q32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.

investing.com2 min